Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment

Havrilesky, Laura J.; Lim, Stephanie; Ehrisman, Jessie; Lorenzo, A.; Secord, Angeles Alvarez; Yang, Jui‐Chen; Gonzalez, Juan Marcos; Reed, Shelby D.

doi:10.1016/j.ygyno.2020.01.026

Cited by 22 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to differences in nature and characteristics of the disease, the results may not represent the preferences of patients with other types of chronic diseases. Although prior DCEs [44][45][46][47][48] made conclusions that were similar to ours in terms of the relative importance of technology attributes regarding benefits and risks. Future studies need to enrol patients with other diseases and conduct subgroup analyses to identify variations in patients' preferences across different types of diseases.…”

Section: Strengths and Limitationssupporting

confidence: 74%

“…Comparison with other studies Our findings of patients valuing the effectiveness and safety of medical technologies were consistent with the results by prior studies from other countries which aimed to investigate patients' preferences for the treatment of chronic diseases. [44][45][46][47][48] Our study confirmed that new technologies that could increase health benefits and minimise potential risks were preferred by patients.…”

Section: Summary Of the Findingssupporting

confidence: 70%

See 1 more Smart Citation

Patients’ preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment

Geng

Chen²,

Bao

et al. 2020

BMJ Open

View full text Add to dashboard Cite

ObjectivesOur study aimed to inform insurance decision-making in China by investigating patients’ preferences for insurance coverage of new technologies for treating chronic diseases.DesignWe identified six attributes of new medical technologies for treating chronic diseases and used Bayesian-efficient design to generate choice sets for a discrete choice experiment (DCE). After conducting the DCE, we analysed the data by mixed logit regression to examine patient-reported preferences for each attribute.SettingThe DCE was conducted with patients in six tertiary hospitals from four cities in Jiangsu province.ParticipantsPatients aged 18 years or older with a history of diabetes or hypertension and taking medications regularly for more than 1 year were recruited (n=408).ResultsThe technology attributes regarding expected gains in health outcomes from the treatment, high likelihood of effective treatment and low incidence of serious adverse events were significant, positive predictors of choice by the study patients (p<0.01). The out-of-pocket cost was a significant, negative attribute for the entire study sample (β = −0.258, p<0.01) and for the patients with Urban-Rural Residents Basic Medical Insurance (URRBMI) (β = −0.511, p<0.01), but not for all the patients with Urban Employees Basic Medical Insurance (UEBMI) (β = −0.071, p>0.05). The severity of target disease was valued by patients with lower EQ-5D-5L index value as well as URRBMI enrollees.ConclusionsPatients highly valued the health benefits and risks of new technologies, which were closely linked to their feelings of disease and perceptions of health-related quality of life. However, there existed heterogeneity in preferences between URRBMI and UEBMI patients. Further efforts should be made to reduce the gap between insurance schemes and make safe and cost-effective new technologies as a priority for health insurance reimbursement.

show abstract

Section: Strengths and Limitationssupporting

confidence: 74%

Section: Summary Of the Findingssupporting

confidence: 70%

Patients’ preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment

Geng

Chen²,

Bao

et al. 2020

BMJ Open

View full text Add to dashboard Cite

show abstract

“…A consequence of reimbursement when value is not established is the use of healthcare budget that could have been used on more effective therapies. 2,43,44 A further financial consequence of delayed access is the lower than expected revenue for the manufacturer; this is felt immediately by the manufacturer but also has a longer term impact on patients because it puts at risk the development of new, innovative drugs, which is often costintensive. 45 To manage risks from payer coverage of new treatments while supporting early access, when possible, we first need to agree when it is reasonable to expect mature OS data and when it may not be.…”

Section: Consequences Of Decision-making In the Absence Of Mature Os Datamentioning

confidence: 99%

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

Lux¹,

Ciani²,

Dunlop³

et al. 2021

CMAR

View full text Add to dashboard Cite

“…15 This technique identifies the relative importance of different features (ie, attributes) of a product or treatment through experimental manipulation and forced trade-offs and has been successfully applied in orthopedic, gynecological, and cardiothoracic surgery to better inform clinical decision making. 4,6,7,16 An attribute is a characteristic of a product (eg, color), made up of various levels or degrees of that characteristic (eg, red, yellow, blue). These attributes and levels are combined to create multiple scenarios and sequentially presented to the respondent.…”

Section: Conjoint Analysismentioning

confidence: 99%

Evaluating Treatment Preferences and Perceptions of a Prosthetic Versus a Transplanted Hand

et al. 2021

View full text Add to dashboard Cite

Introduction: This study used a conjoint analysis-based survey to assess which factors are most influential when considering treatment with a prosthesis or transplant after a unilateral hand amputation. Methods: Overall, 469 respondents were recruited using Amazon Mechanical Turk and asked to assume that they experienced a hand amputation. To determine preferences for a prosthetic, respondents chose among 11 pairs of alternatives with variations in the following attributes: appearance, function, maintenance, and learning time. Respondents were then presented with descriptions of the risks and outcomes of hand transplantation. The most compelling reasons for and against a transplant were determined and characteristics predictive of support for a transplant were identified. Results: The most important attributes for a prosthesis were "lifelike appearance" and "myolectric function." For hand transplantation, respondents were most concerned about immunosuppression side effects (n = 323, 69%) and the intense nature of surgery (n = 275, 59%), whereas the most positive benefit was the concept of the transplant being "natural" (n = 339, 72%). When faced with the choice of a hand transplant or a prosthetic, approximately 50% of respondents chose a transplantation. Younger age, previous medical experiences, a perceived "familiarity with medical issues," and the regular attendance of religious services were associated with strong support for a hand transplantation (P < 0.01). Conclusions: When considering a hand prosthesis, respondents are motivated most by appearance and function. Meanwhile, with hand transplantation, the risks of immunosuppression and the intense nature of surgery and recovery are predominant concerns. These findings may help inform patient-physician discussions when considering treatment after unilateral hand amputation.

show abstract

Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment

Cited by 22 publications

References 34 publications

Patients’ preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment

Patients’ preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

Evaluating Treatment Preferences and Perceptions of a Prosthetic Versus a Transplanted Hand

Contact Info

Product

Resources

About